New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
08:05 EDTXNCRXencor appoints John Desjarlais as Chief Scientific Officer
Xencor announced the appointment of John R. Desjarlais to senior vice president of research and chief scientific officer. Desjarlais joined Xencor in 2001 and was promoted to vice president of research in 2006, where he oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of drug candidates.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
08:03 EDTXNCRXencor and Novo Nordisk partner for novel drug development
Subscribe for More Information
December 7, 2014
14:59 EDTXNCRMorphoSys and Xencor publish final results from Phase 1/2a trial of MOR208
MorphoSys and Xencor (XNCR) announced the publication of final results of a Phase 1/2a trial evaluating MOR208 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. MOR208 was in-licensed by MorphoSys from Xencor in 2010.The results demonstrate that the drug was well tolerated and achieved durable responses in a high risk and poor prognosis patient population with significant progression-free survival achieved.
December 6, 2014
09:38 EDTXNCRXencor to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use